Knowledge Library

Developing drug-induced resistant tumor models for efficacy evaluation of next-generation anticancer therapies

The therapeutic landscape of cancer has been transformed over the last few decades. Our understanding of cancer and its therapeutic approach has improved greatly due to advanced cancer biology, functional imaging and next–generation sequencing. One of the key challenges in cancer therapy is how to effectively kill cancer cells while leaving normal cells intact. As …Read More >

Resource Type: Poster
Resource Topic: Biomarkers, in vivo Pharmacology, Oncology, Target Identification and Validation, Tumor Models

VIEW

Developing a panel of orthotopic syngeneic tumor models for IO drug discovery

The efficacy of immuno-oncology therapies needs to be evaluated in animal models with functional immune systems. Syngeneic tumor models are established by inoculating mouse cancer cell lines into immunocompetent mice with the same genetic background. The host mice have complete immune activity and show histocompatibility with homograft tumor tissues, which can maximize the simulation of …Read More >

Resource Type: Poster
Resource Topic: Antibodies, in vivo Pharmacology, Lead Optimization, Oncology, Target Identification and Validation, Tumor Models

VIEW

Development of an integrated in vitro and in vivo OVA-specific system for cancer vaccine discovery

We have established an advanced and integrated in vitro and in vivo platform for various types of cancer vaccines, including peptide vaccines, mRNA vaccines, DC vaccines and more. Ovalbumin (OVA) is a key model antigen which has been widely used in vaccination experiments. Here we established an OVA overexpressed system based on different types of …Read More >

Resource Type: Latest Science, Poster
Resource Topic: Biomarkers, Cell-based Assays, Immunology, in vitro biology, Lead Optimization, Oncology, Target Identification and Validation, Target-Specific Assays, Tumor Models

VIEW

Mouse hind limb tumor metastatic model to evaluate prophylaxis and treatment

We have established and optimized a robust tumor bone metastasis mouse model, which recapitulates the tumor metastasis progression from circulation to bone colonization, and provides a window for evaluating prophylaxis and treatment. Specifically, we inoculated two breast cancer cell lines, JIMT-1 and MDA-MB-231, each with high metastatic potential, into the mouse intra-caudal artery. By detection …Read More >

Resource Type: Latest Science, Poster
Resource Topic: Biomarkers, in vivo Pharmacology, Lead Optimization, Oncology, Tumor Models

VIEW

Evaluating cancer therapies combining radiotherapy with immunotherapy or inhibitors of the DNA damage response

Ionizing radiation has largely been recognized as a local targeted therapy by a variety of mechanisms, including inducing direct DNA damage of cancerous tissue or contributing to systemic antitumor immunity. The capacity of cancer cells to recognize DNA damages and initiate repair plays a major role in radio-resistance. Furthermore, the irradiated tumor cell death can …Read More >

Resource Type: Latest Science, Poster
Resource Topic: Cell-based Assays, Immunology, in vitro biology, Oncology, Tumor Models

VIEW

Meeting Neurodegenerative Disease Head-On with Emerging Drug Discovery Strategies

Chronic neurodegenerative diseases encompass a variety of progressive conditions that affect neurons, including Huntington’s disease, Parkinson’s disease, Alzheimer’s disease, and other forms of dementia. They are among the most common and challenging central nervous system (CNS) diseases. “Many companies had stopped their research program into neurodegenerative diseases, but now sophisticated technology advances have became more broadly …Read More >

Resource Type: Presentation, White Paper
Resource Topic: Biomarkers, Cell-based Assays, Central Nervous System & Pain, Chemical Biology and Proteomics, Hit-to-Lead, in silico services, in vivo Pharmacology, Lead Optimization, Rare Diseases

VIEW

Evaluation of the efficacy of ADC in vitro and in vivo

Abstract Antibody drug conjugates (ADCs) are promising complexes with therapeutic potential that aimed to the treatment of solid tumor and hematological malignancies. Compared with the therapeutic monoclonal antibody, an ADC-derived monoclonal antibody is conjugated with cytotoxic agents (payloads) which can deliver potent cellular toxins to targeted cancer cells specifically. We have established a state-of-the-art platform …Read More >

Resource Type: Poster
Resource Topic: Antibody Drug Conjugate, Biochemical Assays, Biomarkers, Cell-based Assays, Immunology, in vitro biology, Lead Optimization, Oncology, Tumor Models

VIEW

Structure determination: comparison of methods

WuXi AppTec offers comprehensive structural generation solutions for today´s challenging targets. Our experts provide insights and data to support hit finding through to lead optimization.

Resource Type: Brochure, Infographic
Resource Topic: Biophysical Assays, Cells and Protein Science, Hit Finding, Hit-to-Lead, Lead Optimization, Structural Biology, Target Identification and Validation

VIEW

WuXi Discovery Services Newsletter: November 2021

Resource Type: Newsletter
Resource Topic: Biophysical Assays, Central Nervous System & Pain, Oligonucleotides, Rare Diseases, Targeted Protein Degradation

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!